"Response "to" FDA questions Q3" FDA had questions about IND submission; which is expected. Response "to" those questions in Q3 means exactly that. I think FDA approval of concept is coming only after BMSN responds "back" on those initial questions- IMO. Can anyone contradict my opinion? Hopefully I am wrong.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.